PurMinds Enterprises, Inc. Files Fiscal 2026 Second Quarter Financials on OTC Markets; Launches PCAOB Audit to Position for OTCQB/QX Uplisting
Rhea-AI Summary
PurMinds Enterprises (OTC:PFSF) filed fiscal 2026 Q2 financials for the quarter ended March 31, 2026 and is executing a PCAOB audit to support an OTCQB/OTCQX uplisting.
The company reported zero revenue, higher operating expenses, a larger net loss, major balance sheet cleanup, and over $2.25 million in private capital raised or committed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- Cancelled 1,500,000 legacy common shares and all Series A and 1,000 Series B preferred shares
- Eliminated $300,000 in legacy promissory note liabilities
- Raised or committed over $2.25 million in private capital since the RTO
- Allocated $350,400 to clinical pipeline and diagnostic platform development
- Completed SR&ED tax audit, securing non-dilutive capital for Canadian operations
- PCAOB audit underway, targeted completion by end of June or early July 2026 to support uplisting
Negative
- Revenue and gross profit were zero in fiscal Q2 2026, unchanged year over year
- Operating expenses increased to $814,000, up $500,000 versus Q2 fiscal 2025
- Net loss widened to $922,000 versus $182,000 in the prior-year quarter
- Other expense, net was $108,000 versus other income, net of $132,000 a year earlier
News Market Reaction – PFSF
On the day this news was published, PFSF declined 14.00%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
The Company's Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A) has been published on the OTC Markets platform as part of this quarterly disclosure, adhering to the comprehensive reporting standards typical of a reporting issuer, even though the Company is not currently designated as a reporting issuer.
Investors and shareholders can review the detailed operational analysis specifically on pages 18–23 of the filed quarterly report at:
https://www.otcmarkets.com/file/company/financial-report/564647/content
The quarterly filing also outlines a comprehensive operational and balance sheet cleanup of legacy shell obligations, establishing a streamlined financial foundation to advance its proprietary neurological drug pipeline and advanced diagnostic applications.
PCAOB Audit Progress & Strategic Up-listing Mandate
To further its commitment to institutional-grade transparency and to accelerate its capital markets strategy, the Company is currently in the process of executing its PCAOB audit under the leadership of its recently appointed CFO and COO, Angelo Pizzuto. Achieving a finalized PCAOB audit is a strict regulatory requirement that supports the Company's planned uplisting application to the OTCQB or OTCQX market tiers.
The PCAOB audit pre-work formally commenced on May 6, 2026, with the hiring of an independent, third-party pre-audit accounting preparation firm. This firm has been actively optimizing the Company's financial records and preparing technical accounting memos to ensure total audit readiness. Because this third-party team has a collaborative working relationship with the incoming principal PCAOB audit firm, it will actively drive the final data handoff, facilitating a seamless transition and minimizing standard auditing friction.
The entire audit process is expected to be completed by the end of June or early July 2026.
Concurrently, the Company has initiated the formal corporate name change and ticker symbol change request process. Management and its legal team are actively reviewing the necessary regulatory components to ensure these changes are processed and finalized in a timely manner.
Immediately upon the sign-off and publication of the PCAOB-audited financials, the Company will coordinate with an institutional Market Maker to submit a Rule 15c2-11 application with FINRA to permanently remove any lingering shell restrictions and re-establish a transparent, robust public quote under its newly approved identity.
Q1 2026 Financial and Corporate Highlights:
- Balance Sheet Optimization: Achieved the formal cancellation and return of 1,500,000 legacy common shares, the complete redemption and retirement of all outstanding Series A Preferred stock, and the cancellation of 1,000 Series B Preferred shares. Additionally, the Company finalized the complete settlement and elimination of
$300,000 - Robust Capital Inflows: Total private capital raised or formally committed since the inception of the RTO has exceeded
$2.25 million $2,101,781 $40,000 $428,037 $125,000 - Strategic R&D Deployments: Allocated
$350,400 $250,000 $100,400 U.S . clinical research institution for collaborative neuromedicine programs. - Resolution of Tax Contingencies: Finalized a regulatory government audit of historical Canadian Scientific Research and Experimental Development (SR&ED) tax credits, securing a substantial portion of the claim as non-dilutive capital flowing into the Canadian operating infrastructure.
- Financial Results: Revenue and gross profit were zero, unchanged vs. Q2 of fiscal 2025. Total operating expenses in Q2 fiscal 2026 increased by
$500,000 $814,000 $350,000 $108,000 $132,000 $922,000 $(.00) per share, vs. a net loss of$182,000 $(.00) per share, in Q2 of the prior fiscal year.
"Moving deeper into fiscal 2026, management is strictly execution-focused, moving past corporate restructuring and entering a high-growth public market phase," jointly stated Janet Qi, CEO, and Angelo Pizzuto, CFO of PurMinds. "Clearing our legacy obligations, bringing in strong private investment capital, executing this PCAOB audit, and driving our strategic commercialization initiatives are the foundational steps required to scale our corporate runway and achieve our targeted clinical milestones over the next 24 months."
About PurMinds Enterprises, Inc.
PurMinds is a biotech company building an integrated precision medicine ecosystem through the convergence of advanced therapeutics (with focus on neurological disorders), decentralized diagnostics, and data-driven healthcare intelligence. Central to this strategy is PurMinds' exclusive partnership with SpectroChip Global Inc.
SpectroChip has developed the world's first fingernail-sized photonic chip-based diagnostic system integrating the core functionalities of spectrophotometry, chromatography, and lateral flow immunoassays (LFIA). The full-spectrum handheld or pocket-sized spectrometer can bring hospital-grade diagnostics directly to clinics, pharmacies, community health centers, and patients' bedside. In this partnership, PurMinds is the exclusive global partner to develop and supply all rapid diagnostic kits used in the SpectroChip POCT platform. Together, PurMinds and SpectroChip are developing a decentralized POCT ecosystem that combines real-time diagnostics, longitudinal health monitoring, data-driven analytics, and personalized therapeutic pathways into a unified healthcare intelligence platform, while building a scalable, recurring-revenue infrastructure designed to support sustainable growth and long-term enterprise value.
For more information, visit www.PurMinds.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding the Company's audit timelines, commercialization efforts, potential capital raises, and upcoming FINRA submissions. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. The Company undertakes no obligation to update these statements should circumstances change.
View original content to download multimedia:https://www.prnewswire.com/news-releases/purminds-enterprises-inc-files-fiscal-2026-second-quarter-financials-on-otc-markets-launches-pcaob-audit-to-position-for-otcqbqx-uplisting-302799088.html
SOURCE PurMinds Enterprises, Inc.